Publications

Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Kidney International. (2015) 88, 1187–1194; doi:10.1038/ki.2015.203; published online 8 July 2015.

Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron. Nephrol Dial Transplant (2015) 30: 2019 – 2026 doi: 10.1093/ndt/gfv277 Advance Access publication 13

Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century Drugs (2016). DOI 10.1007/s40265-016-0569-0; Published online 18 April 2016

Triferic Human Intravenous (IV) Pharmacokinetic StudyThe Journal of Clinical Pharmacology (2016). DOI:10.1002/jcph.819